GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:00508528 | Esophagus | ESCC | T cell receptor signaling pathway | 73/8552 | 123/18723 | 1.54e-03 | 7.24e-03 | 73 |
GO:000181916 | Esophagus | ESCC | positive regulation of cytokine production | 244/8552 | 467/18723 | 2.29e-03 | 1.01e-02 | 244 |
GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
GO:004209816 | Oral cavity | OSCC | T cell proliferation | 100/7305 | 199/18723 | 7.93e-04 | 4.27e-03 | 100 |
GO:000181910 | Oral cavity | OSCC | positive regulation of cytokine production | 213/7305 | 467/18723 | 1.93e-03 | 8.96e-03 | 213 |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
GO:004211017 | Oral cavity | LP | T cell activation | 146/4623 | 487/18723 | 4.13e-03 | 2.66e-02 | 146 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:004211023 | Oral cavity | EOLP | T cell activation | 111/2218 | 487/18723 | 4.67e-12 | 8.17e-10 | 111 |
GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
GO:005085214 | Oral cavity | EOLP | T cell receptor signaling pathway | 33/2218 | 123/18723 | 4.19e-06 | 8.76e-05 | 33 |
GO:007066112 | Oral cavity | EOLP | leukocyte proliferation | 65/2218 | 318/18723 | 6.86e-06 | 1.33e-04 | 65 |
GO:000181915 | Oral cavity | EOLP | positive regulation of cytokine production | 87/2218 | 467/18723 | 1.08e-05 | 1.92e-04 | 87 |
GO:00024292 | Oral cavity | EOLP | immune response-activating cell surface receptor signaling pathway | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00027572 | Oral cavity | EOLP | immune response-activating signal transduction | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00022534 | Oral cavity | EOLP | activation of immune response | 72/2218 | 375/18723 | 2.18e-05 | 3.35e-04 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BTN3A1 | SNV | Missense_Mutation | novel | c.1228N>T | p.Gly410Trp | p.G410W | O00481 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A06D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
BTN3A1 | SNV | Missense_Mutation | novel | c.1041N>C | p.Lys347Asn | p.K347N | O00481 | protein_coding | tolerated(0.16) | benign(0.062) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
BTN3A1 | SNV | Missense_Mutation | novel | c.1103N>T | p.Pro368Leu | p.P368L | O00481 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | rs747919410 | c.716A>G | p.Asp239Gly | p.D239G | O00481 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | rs563390836 | c.1439N>T | p.Ser480Leu | p.S480L | O00481 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | | c.643N>A | p.Gly215Arg | p.G215R | O00481 | protein_coding | tolerated(0.17) | probably_damaging(0.994) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | | c.834N>T | p.Lys278Asn | p.K278N | O00481 | protein_coding | tolerated(0.37) | benign(0.031) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | | c.1102N>T | p.Pro368Ser | p.P368S | O00481 | protein_coding | deleterious(0.02) | benign(0.371) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | rs374921833 | c.43N>T | p.Arg15Cys | p.R15C | O00481 | protein_coding | tolerated(0.18) | benign(0.2) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BTN3A1 | SNV | Missense_Mutation | | c.955T>C | p.Tyr319His | p.Y319H | O00481 | protein_coding | tolerated_low_confidence(0.08) | benign(0.365) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |